| 1/26 | US=16 / Estatística Verma M. Proteomics and cancer epidemiology. In: ___. Cancer epidemiology. New York: Humana Press, 2009. p. 197-215. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1. CANCER. EPIDEMIOLOGIA; PROTEOMICA; INTELIGENCIA ARTIFICIAL; POLIACRILAMIDA ELETROFORESE EM GEL (PAGE); BIOMARCADOR; CROMATINA; EPIGENETICA; HISTONA; DESSORCAO DE IONS INDUZIDA POR LASER (MALDI); ESPECTROMETRIA; METILACAO; PROTEOMICA; AVALIACAO DE RISCO; SELDI; TRIAGEM |
| 2/26 | US=16 / Estatística Kumar D, Verma M. Methods in cancer epigenetics and epidemiology. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 273-88. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1. CANCER. EPIDEMIOLOGIA; EPIGENETICA; ACETILACAO; BIOMARCADOR; CROMATINA; EPIGENETICA; HISTONA; HISTONA DESACETILASE (HDAC); HISTONA ACETILTRANSFERASE (HAT); METILACAO; METILTRANSFERASE; AVALIACAO DE RISCO; TRIAGEM |
| 3/26 | US=6 / Quimioterapia Airley R. Histone deacetylase: an epigenetic drug target. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 255-63. ISBN 978-0-470-09254-5. INIBIDORES DE HDAC; HISTONA DEACETILASE; DROGA EPIGENETICA; HDAC; EMBALAGEM DE DNA |
| 4/26 | US=85 / Biol/Mol Savickiene J, Treigyte G, Magnusson KE, Navakauskiene R. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 321-33. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. CADMIO; LEUCEMIA; APOPTOSE; HISTONA DESACETILASE INIBIDORES; REMODELACAO DA CROMATINA; P21 |
| 5/26 | US=9 / Pediatria Smith MA. Evolving molecularly targeted therapies and biotherapeutics. In: Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott Williams and Wilkins, 2006. p. 366-404. ISBN 978-0-7817-5492-7. ONCOLOGIA PEDIATRICA; CANCER INFANTIL; CRIANCA; BIOTERAPIA; TERAPIA MOLECULAR; APOPTOSE; VIAS DE SINALIZACAO EXTRACELULAR; ENZIMAS HISTONA DESACETILASE; FARNESIL-TRANSFERASE; PROTEASSOMA; ANGIOGENESE |
| 6/26 | US=13 / Biol/Mol Pecorino L. Regulation of gene expression. In: ___. Molecular biology of cancer: mechanisms, targets, and therapeutics. 2nd ed. Oxford: Oxford University Press, 2008. p. 47-68. ISBN 978-0-19-921148-7. REGULACAO DA EXPRESSAO GENICA; FATORES DE TRANSCRICAO; REGULACAO TRANSCRICIONAL; ESTRUTURA DA CROMATINA; REGULACAO EPIGENETICA DA TRANSCRICAO; MODIFICACAO DA HISTONA; METILACAO DE DNA; EPIGENETICA; CARCINOGENESE; TELOMERES; TELOMERASE |
| 7/26 | US=33 / Biol/Mol Lewin B. Controlling chromatin structure. In: ___. Genes IX. Boston: Jones & Bartlett Publishers, 2008. p. 796-817. ISBN 0-7637-5222-3. ESTRUTURA DA CROMATINA; HISTONA; ACETILASES; METILACAO; CROMATINA |
| 8/26 | US=33 / Biol/Mol Lewin B. Epigenetic effects are inherited. In: ___. Genes IX. Boston: Jones & Bartlett Publishers, 2008. p. 818-44. ISBN 0-7637-5222-3. EFEITOS EPIGENETICOS; HETEROCROMATINA; HISTONA; METILACAO DO DNA |
| 9/26 | US=39 / Câncer Rosato RR, Grant S. Histone deacetylase inhibitors and anticancer activity. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 115-31. ISBN 978-1-58829-989-5. INIBIDORES HISTONA DEACETILASE; ATIVIDADE ANTICANCER; MECANISMO MOLECULAR; EPIGENETICA |
| 10/26 | US=67 / Biol/Mol Thiagalingam S, Faller DV. The cancer epigenome: cann it be targeted for therapy?. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 97-113. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; EPIGENOMA; METILACAO DO DNA; DNA METIL TRANSFERASE; HISTONA ACETILTRANSFERASE; HISTONA-DESACETILASE; CODIGO DE HISTONAS; CODIGO EPIGENOMICO ATIVA; CODIGO EPIGENOMICO SILENCIADO; INIBIDOR DE HISTONA-DESACETILASE; TERAPIA DO CANCER |
| 11/26 | US=80 / Biol/Mol Gjertsen BT, Sjoholt G. Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 161-87. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. LEUCEMIA MIELOIDE AGUDA; BIOMARCADORES; PHARMACOPROTEOMICS; ACIDO TRANS-RETINOICO; INIBIDORES DE QUINASE DE TIROSINA; HISTONA DEACETILASE INIBIDORES; INIBIDORES DE PROTEASSOMA |
| 12/26 | US=84 / Biol/Mol Leader JE, Frontelo MP, Lechleider RJ. TGF-B superfamily members in normal and tumor biology: histone methyltransferase and smad interactions in BMP signaling. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 383-93. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. HISTONA METILTRANSFERASE; SMAD; BMP; RECEPTORES DE CELULAS DE SUPERFICIE; FAMILIA SUV39H; CROMATINA |
| 13/26 | US=86 / Biol/Mol Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HAC inhibitor-induced apoptosis. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 261-98. (Advances in Experimental Medicina and Biology volume 615) ISBN 978-1-4020-6553-8. INIBIDORES DE HISTONA DESACETILASE; CANCER; APOPTOSE INDUZIDA POR INIBIDORES; INIBIDORES HDAC; HAT; SAHA; MS-275; TSA; TRAIL; CASPASE |
| 14/26 | US=111-A / Câncer Molife R, Collins I, Workman P, Kaye SB. Rational drug design of small molecule anticancer agents: early clinical development. In: Alison MR. The cancer handbook. 2nd ed. New Jersey: John Wiley & Sons, 2007. p. 1216-41. ISBN 978-0-470-01852-1. CANCER. TERAPIA; MEDICAMENTOS; AGENTES DE PEQUENAS MOLECULAS ANTICANCER; DESENVOLVIMENTO CLINICO PRECOCE; INIBIDORES HSP 90; CICLINA DEPENDENTE DE INIBIDORES DE QUINASE; HISTONA DEACETILASES; FOSFOINOSITIDEO 3-QUINASE; FOSFATIDILINOSITOL 3-QUINASES |
| 15/26 | US=16 / Urologia Kortenhorst MSQ, Carducci MA, Shabbeer S. Therapeutics: differentiation agents and epigenomic therapies. In: Chung LWK, Isaacs WB, Simons JW. Prostate cancer: biology, genetics, and the new therapeutics. 2ª ed. New Jersey: Humana Press, 2007. p. 411-43. (Contemporary Cancer Research) ISBN 978-1-58829-696-2. CANCER DE PROSTATA; TERAPEUTICA; AGENTES DE DIFERENCIACAO; TERAPIA EPIGENOMICA; ACETILACAO; MODIFICACAO DA CROMATINA; REMODELAMENTO DA CROMATINA; ENSAIOS CLINICOS; EPIGENETICA; HISTONA ACETIL TRANSFERASE; CODIGO DE HISTONAS; INIBIDOR DE HISTONA-DESACETILASE; METILACAO; INIBIDOR METIL TRANSFERASE |
| 16/26 | US=35 / Câncer Fandy T, Carraway H, Gore SD. Molecular therapeutics of AML: modulating gene expression as a therapeutic approach in the treatment of AML. In: Karp JE. Acute myelogenous leukemia. New Jersey: Humana Press, 2007. p. 275-91. (Contemporary Hematology) ISBN 978-1-58829-621-4. LEUCEMIA MIELOIDE AGUDA; METILACAO DO DNA; AGENTE DEMETILANTE; 5-AZACITIDINA; INIBIDOR DA HISTONA DEACETILASE; PROMOTOR HIPER-METILACAO; HISTONA ACETILTRANSFERASE; HISTONA METILTRANSFERASE; DECITABINA |
| 17/26 | US=77-J / Câncer Rodrigues RV. Epigenética e câncer. In: Lopes A, Chammas R, Iyeyasu H. Oncologia para a graduação. 3ª ed. São Paulo: Lemar, 2013. p. 44-53. ISBN 8-5866523-7-0. CANCER; EPIGENETICA; METILACAO DO DNA; HISTONA; CODIGO DE HISTONA; REGULACAO DA EXPRESSAO GENICA; MICRORNAS |
| 18/26 | US=88 / Biol/Mol Tollefsbol T. Role of epigenetics in cancer. In: ___. Cancer epigenetics. Boca Raton: CRC, 2009. p. 1-4. ISBN 978-1-4200-4579-6. |
| 19/26 | US=88 / Biol/Mol McBrian MA, Seligson DB, Kurdistani SK. Histone modifications in cancer biology and prognosis. In: Tollefsbol T. Cancer epigenetics. Boca Raton: CRC, 2009. p. 359-79. ISBN 978-1-4200-4579-6. CANCER; EPIGENETICA; CANCER. PROGNOSTICO; MODIFICACOES DAS HISTONAS; ACETILACAO DA HISTONA; METILACAO DA HISTONA |
| 20/26 | US=88 / Biol/Mol Sargeant AM, Kulp SK, Lu YS, Cheng AL, Chen CS. Histone deacetylase inhibitors in cancer therapy. In: Tollefsbol T. Cancer epigenetics. Boca Raton: CRC, 2009. p. 381-98. ISBN 978-1-4200-4579-6. CANCER; EPIGENETICA; INIBIDORES DA HISTONA DEACETILASE; CANCER. TERAPIA |